• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    12/11/23 4:31:07 PM ET
    $AQB
    $CNTB
    $HLTH
    $INAB
    Meat/Poultry/Fish
    Consumer Staples
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AQB alert in real time by email

    Gainers

    • Connect Biopharma Hldgs (NASDAQ:CNTB) shares increased by 51.1% to $1.36 during Monday's after-market session. The market value of their outstanding shares is at $74.8 million.
    • IN8bio (NASDAQ:INAB) shares rose 14.84% to $1.47. The market value of their outstanding shares is at $47.0 million.
    • Inotiv (NASDAQ:NOTV) shares increased by 13.85% to $3.45. The market value of their outstanding shares is at $88.9 million. As per the press release, Q4 earnings came out today.
    • OneMedNet (NASDAQ:ONMD) shares moved upwards by 10.9% to $1.22. The company's market cap stands at $39.3 million.
    • AquaBounty Techs (NASDAQ:AQB) shares moved upwards by 8.69% to $2.49. The market value of their outstanding shares is at $9.5 million.
    • Cue Health (NASDAQ:HLTH) stock rose 7.38% to $0.32. The company's market cap stands at $49.8 million.

    Losers

    • Assure Hldgs (NASDAQ:IONM) stock fell 12.5% to $0.38 during Monday's after-market session. The company's market cap stands at $2.5 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) stock declined by 7.33% to $0.41. The company's market cap stands at $8.5 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) stock declined by 6.39% to $0.26. The market value of their outstanding shares is at $4.6 million.
    • Onconova Therapeutics (NASDAQ:ONTX) shares decreased by 6.35% to $0.74. The market value of their outstanding shares is at $15.5 million.
    • Exicure (NASDAQ:XCUR) stock decreased by 6.06% to $0.59. The company's market cap stands at $5.0 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock fell 5.46% to $0.31. The company's market cap stands at $26.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AQB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQB
    $CNTB
    $HLTH
    $INAB

    CompanyDatePrice TargetRatingAnalyst
    Connect Biopharma Holdings Limited
    $CNTB
    12/1/2025$9.00Buy
    Lake Street
    Connect Biopharma Holdings Limited
    $CNTB
    10/31/2025$10.00Buy
    BTIG Research
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    Connect Biopharma Holdings Limited
    $CNTB
    6/12/2025$7.00Buy
    H.C. Wainwright
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    Inotiv Inc.
    $NOTV
    5/14/2024$11.50 → $3.75Buy → Hold
    Jefferies
    IN8bio Inc.
    $INAB
    3/18/2024$7.50Buy
    Laidlaw
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $AQB
    $CNTB
    $HLTH
    $INAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Xanthopoulos Kleanthis Gabriel

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/2/26 4:27:54 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Liu Jean I

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/2/26 4:25:01 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Huang James

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/1/26 4:30:16 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $CNTB
    $HLTH
    $INAB
    SEC Filings

    View All

    Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - EXICURE, INC. (0001698530) (Filer)

    4/2/26 4:15:02 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Connect Biopharma Holdings Limited

    10-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    3/31/26 4:10:38 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Holdings Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    3/31/26 4:07:41 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $CNTB
    $HLTH
    $INAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the "Company") (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 11,800 shares of its common stock. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted outside of the Company's 2023 Equity Incentive Plan, with a grant date of April 1, 2026, as an inducement material to the new employees entering into employment with the Company, in ac

    4/3/26 4:00:00 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

    MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet's iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and re

    4/1/26 8:55:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. "We appreciate the FDA's decision that PAS-004 meets the criteria for Fast Track designation for this indication," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "The ability to have early and frequent interactions with the FDA supports our goal to expeditiously develop PAS-004

    4/1/26 7:01:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $CNTB
    $HLTH
    $INAB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AQB
    $CNTB
    $HLTH
    $INAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dumesnil Simon bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 1,333% to 35,833 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:54:08 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $CNTB
    $HLTH
    $INAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Connect Biopharma with a new price target

    Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00

    12/1/25 9:37:24 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Connect Biopharma with a new price target

    BTIG Research initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $10.00

    10/31/25 8:19:20 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on NRx Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/8/25 8:58:39 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $CNTB
    $HLTH
    $INAB
    Leadership Updates

    Live Leadership Updates

    View All

    Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network

    Hope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy.The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits.Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objecti

    3/30/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

    Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical DirectorImmediate expansion is planned in Western Florida and Palm BeachAcquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), today announced the acquisition of a strategic interest in Cohen and Associates, LLC ("Cohen, LLC") and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Dire

    10/20/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQB
    $CNTB
    $HLTH
    $INAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Pasithea Therapeutics Corp.

    SC 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

    11/14/24 3:32:41 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    11/12/24 3:35:37 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AQB
    $CNTB
    $HLTH
    $INAB
    Financials

    Live finance-specific insights

    View All

    Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

    – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –  – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today anno

    3/30/26 7:01:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

    – Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique beneficial effect on bronchodilation – – Mean FEV1 improvements of ~200 - 400 mL were maintained through Day 29 in asthma and COPD patients – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD;

    3/30/26 7:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care